Form 4: Immunocore Holdings Director Acquires Share Options

Director Peter John Ratcliffe acquired 26,198 share options in Immunocore Holdings plc on May 15, 2025.

Summary

• Peter John Ratcliffe, a director of Immunocore Holdings plc, acquired 26,198 share options on May 15, 2025.
• The exercise price of these options is $29.06.
• The options vest on the earlier of May 15, 2026, or the day before the next annual general meeting, contingent upon continuous service.
• The options expire on May 14, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of share option grants to a director. While insider ownership can be a positive signal, this specific event is more procedural.

Positives

• The acquisition of share options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Option grants to directors are a common practice in publicly traded companies, particularly in the biotechnology sector, to align their interests with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market prices at the time of the grant.
• Comparable companies like Adaptimmune Therapeutics or CRISPR Therapeutics also utilize stock options as part of their director compensation packages.

Key Dates

Keywords

Immunocore Holdings, share options, director, acquisition, Ratcliffe, IMCR